Cytokeratin 14 (CK14)

Concentrated Monoclonal Antibody
901-185-101717

BIOCARE MEDICAL

Catalog Number:	**CM 185 B, C**
Description:	0.5, 1.0 ml, concentrated
Dilution:	1:100
Diluent:	Renaissance Background Reducing

Intended Use:
For In Vitro Diagnostic Use
Cytokeratin 14 (CK14) [LL002] is a mouse monoclonal antibody that is intended for laboratory use in the qualitative identification of cytokeratin 14 protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Summary and Explanation:
Cytokeratin 14 (CK14) is a type I (acidic) human intermediate filament protein of 50 kDa, which usually pairs with CK5, a type II (basic) cytokeratin. In neoplastic cells, CK14 is a useful marker in identification of basal cell epithelium in prostate and myoepithelium in breast, and has also been shown to be a marker of squamous cell carcinoma in lung and in other histological types of various cancers (1-8). The CK14 monoclonal antibody is usually cocktailed with CK5 and may be used in a panel of CK5/CK14 + p63 + AMACR (P504S) or CK7/18 to assess neoplasia in prostate biopsies and breast cancers (7,9,10).

Principle of Procedure:
Antigen detection in tissues and cells is a multi-step immunohistochemical process. The initial step binds the primary antibody to its specific epitope. After labeling the antigen with a primary antibody, a secondary antibody is added to bind to the primary antibody. An enzyme label is then added to bind to the secondary antibody; this detection of the bound antibody is evidenced by a colorimetric reaction.

Source: Mouse monoclonal
Species Reactivity: Human
Clone: LL002
Isotype: IgG3
Total Protein Concentration: ~10 mg/ml. Call for lot specific Ig concentration.
Epitope/Antigen: CK14
Cellular Localization: Cytoplasmic
Positive Tissue Control: Prostate

Known Applications:
Immunohistochemistry (formalin-fixed paraffin-embedded tissues)
Supplied As: Buffer with protein carrier and preservative

Storage and Stability:
Store at 2ºC to 8ºC. Do not use after expiration date printed on vial. If reagents are stored under conditions other than those specified in the package insert, they must be verified by the user. Diluted reagents should be used promptly; any remaining reagent should be stored at 2ºC to 8ºC.

Protocol Recommendations:
Peroxide Block: Block for 5 minutes with Biocare's Peroxidazed 1.
Pretreatment: Perform heat retrieval using Biocare's Diva Decloaker. Refer to the Diva Decloaker data sheet for specific instructions.
Protein Block (Optional): Incubate for 5-10 minutes at RT with Biocare's Background Punisher.
Primary Antibody: Incubate for 30 minutes at RT.
Probe: Incubate for 10 minutes at RT with a secondary probe.
Polymer: Incubate for 10-20 minutes at RT with a tertiary polymer.

Protocol Recommendations Cont'd:
Chromogen: Incubate for 5 minutes at RT with Biocare's DAB – OR – Incubate for 5-7 minutes at RT with Biocare's Warp Red.
Counterstain:
Counterstain with hematoxylin. Rinse with deionized water. Apply Tacha's Bluing Solution for 1 minute. Rinse with deionized water.
Technical Note:
This antibody has been standardized with Biocare's MACH 4 detection system. Use TBS buffer for washing steps.
Limitations:
The optimum antibody dilution and protocols for a specific application can vary. These include, but are not limited to fixation, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, as results may vary. The data sheet recommendations and protocols are based on exclusive use of Biocare products. Ultimately, it is the responsibility of the investigator to determine optimal conditions. The clinical interpretation of any positive or negative staining should be evaluated within the context of clinical presentation, morphology and other histopathological criteria by a qualified pathologist. The clinical interpretation of any positive or negative staining should be complemented by morphological studies using proper positive and negative internal and external controls as well as other diagnostic tests.
Quality Control:
Refer to CLSI Quality Standards for Design and Implementation of Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-A2) CLSI Wayne, PA USA (www.clsi.org). 2011
Precautions:
1. This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (NaN_3) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976) (11)
2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come into contact with sensitive areas, wash with copious amounts of water. (12)
3. Microbial contamination of reagents may result in an increase in nonspecific staining.
4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.
5. Do not use reagent after the expiration date printed on the vial.
6. The SDS is available upon request and is located at http://biocare.net.

Troubleshooting:
Follow the antibody specific protocol recommendations according to data sheet provided. If atypical results occur, contact Biocare's Technical Support at 1-800-542-2002.

Biocare Medical
60 Berry Drive
Pacheco, CA 94553
USA

IVD CE

Rev: 062117

EC REP EMERGO EUROPE
Prinsessegracht 20
2514 AP The Hague
The Netherlands

Tel: 800-799-9499 | www.biocare.net | Fax: 925-603-8080

Cytokeratin 14 (CK14)

Concentrated Monoclonal Antibody
901-185-101717

BIOCARE MEDICAL

References:

1. Xue LY, *et al.* Expression of fascin and CK14 in different histological types of cancer and its differential diagnostic significance. Zhonghua Zhong Liu Za Zhi. 2010 Nov;32(11):838-44.
2. Sousa B, *et al.* P-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study. Histol Histopathol. 2010 Aug;25(8):963-74.
3. Thike AA, *et al*. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol. 2010 Jan;23(1):123-33.
4. Laakso M, *et al.* Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol. 2005 Oct;18(10):1321-8.
5. Chen Y, *et al*. The diagnostic value of cytokeratin 5/6, 14, 17, and 18 expression in human non-small cell lung cancer. Oncology. 2011;80(5-6):333-40.
6. Man YG, Zhao C, Chen X. A subset of prostate basal cells lacks the expression of corresponding phenotypic markers. Pathol Res Pract. 2006;202(9):651-62.
7. Paner GP, Luthringer DJ, Amin MB. Best practice in diagnostic immunohistochemistry: prostate carcinoma and its mimics in needle core biopsies. Arch Pathol Lab Med. 2008 Sep;132(9):1388-96.
8. Chu PG, Lyda MH, Weiss LM. Cytokeratin 14 expression in epithelial neoplasms: a survey of 435 cases with emphasis on its value in differentiating squamous cell carcinomas from other epithelial tumours. Histopathology. 2001 Jul;39(1):9-16.
9. Hicks DG. Immunohistochemistry in the diagnostic evaluation of breast lesions. Appl Immunohistochem Mol Morphol. 2011 Dec;19(6):501-5.
10. Tacha DE, *et al*. A Rapid Double Immunostaining Technique with a Single Combination of CK5, CK14, p63, CK7 and CK18 Distinguishes Between Hyperplasia of the Usual Type, Atypical Hyperplasia, Microinvasive and Basal Phenotype Breast Cancers. Mod Pathol. 2009 Jan;22(Supplement 1s):388A.
11. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 "Decontamination of Laboratory Sink Drains to Remove Azide Salts."
12. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.

Biocare Medical
60 Berry Drive
Pacheco, CA 94553
USA

IVD CE

Rev: 062117

EC REP EMERGO EUROPE
Prinsessegracht 20
2514 AP The Hague
The Netherlands

Tel: 800-799-9499 | www.biocare.net | Fax: 925-603-8080